Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation

• Published in: Clinical and Applied Thrombosis/Hemostasis Vol. 23; no. 7; pp. 711 - 724
• Main Authors: Sanmartín-Fernández, Marcelo, Marzal-Martín, Domingo
• Format: Book Review Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.10.2017; SAGE PUBLICATIONS, INC
• Subjects: Anticoagulants; Anticoagulants - therapeutic use; Atrial Fibrillation - complications; Cardiac arrhythmia; Clinical medicine; Embolisms; Factor Xa Inhibitors; Humans; Rivaroxaban - therapeutic use; Stroke; Stroke - prevention & control; clinical practice; real-life patients; rivaroxaban; non-vitamin K antagonist oral anticoagulants; ROCKET-AF; nonvalvular atrial fibrillation
• ISSN: 1076-0296; 1938-2723
• DOI: 10.1177/1076029616668404

Despite direct oral anticoagulants (DOACs) have overcome the most relevant limitations of vitamin K antagonists, many patients with atrial fibrillation are not receiving the appropriate anticoagulant therapy. In addition, when patients are anticoagulated with DOACs, some of them are not taking the dose recommended in the summary of product characteristics. This may be related, at least in part, to the concern about the applicability of findings from randomized clinical trials to real-life patients. In this context, performing studies in daily clinical practice to assess the efficacy and safety of DOACs in real-world setting is mandatory. The aim of this review is to update the current evidence regarding safety of rivaroxaban in clinical practice. The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) showed that rivaroxaban was at least as effective as warfarin for preventing stroke or systemic embolism, with similar rates of major bleeding but with lesser risk of intracranial and fatal bleedings. Data from noninterventional studies and registries have confirmed the good results of ROCKET-AF. Even more, rates of bleeding may be inferior in real-life patients, since they have a lower risk profile than those included in ROCKET-AF.